1. Introduction
Molecular targeted drugs and immune checkpoint blockades have remarkably improved outcomes for patients with advanced non-small cell lung cancer (NSCLC) (1, 2). However, those drugs are not indicated for all advanced NSCLC cases. For such patients, cytotoxic drugs are the main treatment, and the prognosis remains poor.
Here, we report a patient with advanced non-squamous (non-Sq) NSCLC and malignant pleural effusion who was treated with cytotoxic drugs: cisplatin-based induction chemotherapy, followed by pemetrexed maintenance therapy (PMT), to which she achieved a durable complete response (CR) for six years to date, after discontinuing all drug treatments.